Human Genome Epidemiology Literature Finder
|
Records 1 - 11 (of 11 Records) |
| Query Trace: Hyperplasia and CYP3A4[original query] |
|---|
| CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncology reports 0 9 (3): 653-5. Tayeb Mohammed T, Clark Caroline, Sharp Linda, Haites Neva E, Rooney Patrick H, Murray Graeme I, Payne Simon N L, McLeod Howard |
| CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. British journal of cancer 2003 Mar 88 (6): 928-32. Tayeb M T, Clark C, Haites N E, Sharp L, Murray G I, McLeod H |
| CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review. American journal of epidemiology 2004 Nov 160 (9): 825-41. Keshava Channa, McCanlies Erin C, Weston Ainsl |
| Joint effects of inflammation and androgen metabolism on prostate cancer severity. International journal of cancer. Journal international du cancer 2008 Sep 123 (6): 1385-9. Rebbeck Timothy R, Rennert Hanna, Walker Amy H, Panossian Saarene, Tran Teo, Walker Kyle, Spangler Elaine, Patacsil-Coomes Margerie, Sachdeva Rajeev, Wein Alan J, Malkowicz S Bruce, Zeigler-Johnson Charni |
| Association of polymorphisms in CYP19A1 and CYP3A4 genes with lower urinary tract symptoms, prostate volume, uroflow and PSA in a population-based sample. World journal of urology 2011 Apr 29 (2): 143-8. Berges Richard, Gsur Andrea, Feik Elisabeth, Höfner Klaus, Senge Theodor, Pientka Ludger, Baierl Andreas, Michel Martin C, Ponholzer Anton, Madersbacher Steph |
| ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients. European journal of clinical pharmacology 2013 Mar 69 (3): 385-93. García Montserrat, Macías Rosa María, Cubero Juan José, Benítez Julio, Caravaca Francisco, Gervasini Guiller |
| The influence of UGT2B7, UGT1A8, MDR1, ALDH, ADH, CYP3A4 and CYP3A5 genetic polymorphisms on the pharmacokinetics of silodosin in healthy Chinese volunteers. Drug metabolism and pharmacokinetics 2012 Dec . Wang Z, Xiang Q, Cui Y, Zhao X, Zhou Y |
| Genetic variants in 5p13.2 and 7q21.1 are associated with treatment for benign prostatic hyperplasia with the ?-adrenergic receptor antagonist. The aging male : the official journal of the International Society for the Study of the Aging Male 2017 Aug 1-7. Qian Xiaoqiang, Xu Ding, Liu Hailong, Lin Xiaoling, Yu Yongjiang, Kang Jian, Sheng Xujun, Xu Jianfeng, Zheng Siqun, Xu Danfeng, Qi J |
| Preliminary Pharmacogenomic-Based Predictive Models of Tamoxifen Response in Hormone-dependent Chilean Breast Cancer Patients. Frontiers in pharmacology 2021 12 12 661443. Miranda Carla, Galleguillos Macarena, Torres Roberto, Tardón Karla, Cáceres Dante D, Lee Kuen, Redal María A, Varela Nelson M, Quiñones Luis |
| Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele. Archives of pharmacal research 2021 11 44 (11): 1037-1049. Cho Chang-Keun, Kang Pureum, Park Hye-Jung, Lee Yun Jeong, Bae Jung-Woo, Jang Choon-Gon, Lee Seok-Yo |
| Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin. Frontiers in pharmacology 2021 10 12 718281. Villapalos-García Gonzalo, Zubiaur Pablo, Navares-Gómez Marcos, Saiz-Rodríguez Miriam, Mejía-Abril Gina, Martín-Vílchez Samuel, Román Manuel, Ochoa Dolores, Abad-Santos Francis |
- Page last reviewed:Oct 1, 2023
- Page last updated:Dec 04, 2023
- Content source: